Retrospective analysis of head and neck cancer patients successfully treated with chemoradiation plus nimotuzumab.

• DOI: 10.1200/jco.2011.29.15_suppl.e16013
• Publication Date: 2017-02-23T13:58:03Z
• Authors: S. M. Karandikar; K. Bokil; S. P. Deshmukh; S. Basu; B. Shinde; H. Patil; N. Gupta
• Keywords: Nimotuzumab

e16013 Background: Nimotuzumab with chemoradiation is found to be efficacious and safe in treatment of locally advanced squamous cell carcinoma head neck (LASCCHN). We did retrospective analysis cancer patients at single center treated this combination from December 2006 2010. Methods: Sixteen SCCHN stage I IVa who either were not willing or ineligible for surgical resection, analyzed. Treatment included Cisplatin dose (40 mg/m2) once weekly six weeks; Radiotherapy was used 60-66 Gy by conventional radiotherapy IMRT. as 200mg Intravenous infusion 60 minutes, a week 6 weeks. Results:There 9 male 7 female patients, (median age, 54 years; range, 29 74 ECOG status 0-1; oropharynx - 11, larynx – 4, hypopharynx 1, 2, 5, 3, stages IV respectively). All completed cycles nimotuzumab. The disease control rate 24 weeks post 81% 12 CR, 1 patient SD, while 3 showed progressive during second, third, fifth month follow up. overall survival all ranged 10 months 33 till There no grade III adverse event related nimotuzumab it well tolerated. Conclusions: This supports that an effective can lead long term benefits. Large clinical trials are underway further validate these findings.